Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Chinese Journal of Neuromedicine ; (12): 231-236, 2013.
Article in Chinese | WPRIM | ID: wpr-1033732

ABSTRACT

Objective To investigate the effect of peptide Tat-GluR6-9c on phosphorylations and protein expressions of mixed-lineage kinase 3 (MLK3),mitogen-activated protein kinase kinase 7 (MKK7) and c-Jun NH2-terminal kinase (JNK),and its effect on hippocampus CA1 region neuronal cell injury induced by cerebral ischemia followed by reperfusion.Methods Twenty four adult male SD rats were randomly divided into sham-operated group,ischemia-reperfusion group (I/R),Tat-GluR6-AA treatment group and Tat-GluR6-9c treatment group (n=6).Four-vessel occlusion method was employed to establish the cerebral ischemia models in the later 3 groups.The effects of peptide Tat-GluR6-9c on the phosphorylations and protein expressions of MLK3 (6 h after the reperfusion) and JNK (3 d after the reperfusion) were detected by Western blotting; the effects ofpeptide Tat-GluR6-9c on the phosphorylation and protein expression of MLK7 (1 d after the reperfusion) were detected by Western blotting and immunohistochemistry.Cresyl Violet (CV) staining was employed to examine the survival of CA1 pyramidal cells in the hippocampus.Results The phosphorylation of MLK3,MKK7 and JNK in Tat-GluR6-9c treatment group was significantly less than that in I/R group and Tat-GluR6-AA treatment group (P<0.05).As compared with I/R group and Tat-GluR6-AA group,peptide Tat-GluR6-9c group could obviously increase the number of neuron cells (P<0.05).Conclusion Peptide Tat-GluR6-9c has a protective effect on neuron in CA1 region of hippocampus following cerebral ischemia-reperfusion by significantly decreasing the phosphorylations ofMLK3,MKK7 and JNK.

2.
Article in Chinese | WPRIM | ID: wpr-267859

ABSTRACT

The aim of study was to explore the frequency of ABO type IgM antibody in infants younger than six months. 309 hospitalized infants younger than six months were selected at first and their EDTA K(3) anticoagulant blood samples were taken. All the infants were divided into five groups: neonates within 1 week as group I; neonates aged 8 to 14 days as group II; neonates aged 15 days to 1 month as group III; infants aged two to 3 months as group IV and infants aged 4 to 6 months as group V. The monocolonal anti-A, anti-B serums, A cells, B cells and O cells were utilized to carried out the blood typing with tube test. The results indicated that from 309 samples tested 33 AB type sample were excluded. Out of the remains of 276 samples, 29 of 46 samples in group I were positive and with the ABO type consistent rate 63% (29/46); 41 of 64 samples in group II were positive and with the ABO type consistent rate 64% (41/64); 47 of 74 samples in group III were positive and with the ABO type consistent rate 63% (47/74); 28 of 45 samples in group IV were positive and with the ABO type consistent rate 62% (28/45); 40 of 47 samples in group V were positive and with the ABO type consistent rate 85%. It is concluded that the ABO type IgM antibody appear in most infants younger than six months and these IgM antibodies may be regarded as the important evidence for ABO typing in infants.


Subject(s)
Female , Humans , Infant , Male , ABO Blood-Group System , Allergy and Immunology , Antibodies, Anti-Idiotypic , Blood , Allergy and Immunology
SELECTION OF CITATIONS
SEARCH DETAIL